User: Guest  Login
Title:

The role of azacitidine in the management of myelodysplastic syndromes (MDS).

Document type:
Journal Article
Author(s):
Götze, K; Müller-Thomas, C; Peschel, C
Abstract:
Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for transformation to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms but has no effect on the natural course of the disease. The recent approval of the demethylating agent azacitidine represents a significant advance in the treatment of MDS. The results of...     »
Journal title abbreviation:
Cancer Manag. Res.
Year:
2009
Journal volume:
1
Pages contribution:
119-30
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/21188130
Print-ISSN:
1179-1322
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX